Imatinib-induced Extensive Hyperpigmentation in a Case of Chronic Myeloid Leukemia

Imatinib, a tyrosine kinase inhibitor, is well known to cause hypopigmentation because of its inhibitory effect on melanocytes. Herewith we report a case of chronic myeloid leukemia who developed extensive hyperpigmentation following imatinib therapy.

Detalles Bibliográficos
Autores principales: Balasubramanian, Pradeep, Jagadeesan, Soumya, Thomas, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
E-IJD Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601460/
https://www.ncbi.nlm.nih.gov/pubmed/26538739
http://dx.doi.org/10.4103/0019-5154.164447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601460/
https://www.ncbi.nlm.nih.gov/pubmed/26538739
http://dx.doi.org/10.4103/0019-5154.164447

Ejemplares similares